← Back to Search

Topical medication

Duobrii Lotion for Plaque Psoriasis

Phase 3
Recruiting
Led By Edward Lain, MD, MBA
Research Sponsored by Austin Institute for Clinical Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Freely provides both verbal and written informed consent
Is in good general health based on the subject's medical history
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 weeks
Awards & highlights

Study Summary

This trial will test a new cream for people with mild plaque psoriasis to see if it is safe and effective.

Eligible Conditions
  • Plaque Psoriasis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment Success by Percent Investigators Global Assessment (IGA)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Treatment Group BExperimental Treatment2 Interventions
Subjects whose baseline Itch and/or Burning/Stinging Score is greater than or equal to 2 (moderate), in addition to one tube of Duobrii along with one jar of CeraVe cream, the participant will be given a tube of hydrocortisone 1% cream and instructed to apply to the treatment area twice daily for 5 days, along with CeraVe cream. Starting at day 6 and ongoing, subjects will be instructed to discontinue the hydrocortisone cream and initiate Duobrii application every night, while continuing the CeraVe cream twice daily.
Group II: Treatment Group AExperimental Treatment2 Interventions
Subjects whose baseline Itch and/or Burning/Stinging Score is less than 2 (moderate), one tube of Duobrii along with one jar of CeraVe cream, will be dispensed to the subject at the Baseline visit. The study participant will be instructed to apply the CeraVe cream to the treatment area twice daily and advised to apply a thin layer of the Duobrii only to the affected skin once daily in the evening.

Find a Location

Who is running the clinical trial?

Austin Institute for Clinical ResearchLead Sponsor
4 Previous Clinical Trials
105 Total Patients Enrolled
OrthoDermatologicsUNKNOWN
Edward Lain, MD, MBAPrincipal InvestigatorAustin Institute for Clinical Research
5 Previous Clinical Trials
136 Total Patients Enrolled

Media Library

Duobrii 0.01 % / 0.045 % Topical Lotion (Topical medication) Clinical Trial Eligibility Overview. Trial Name: NCT05203315 — Phase 3
Plaque Psoriasis Research Study Groups: Treatment Group A, Treatment Group B
Plaque Psoriasis Clinical Trial 2023: Duobrii 0.01 % / 0.045 % Topical Lotion Highlights & Side Effects. Trial Name: NCT05203315 — Phase 3
Duobrii 0.01 % / 0.045 % Topical Lotion (Topical medication) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05203315 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are investigators still looking for test subjects?

"That is correct. The clinical trial mentioned is still recruiting patients, as denoted on the website clinicaltrials.gov. This particular study was first posted on 1/17/2022 and edited most recently on 3/8/2022; at present, they are seeking 40 participants from 2 different locations."

Answered by AI

Could you briefly touch on the scope of this clinical trial?

"The most recent information on clinicaltrials.gov affirms that this study is still actively looking for patients to enroll. The trial was originally posted on January 17th, 2022 and updated March 8th, of the same year. There are 40 positions available at 2 different sites."

Answered by AI

Does this research opportunity have an age limit?

"This specific clinical trial is only for patients aged 18-99. However, there are a total of 32 clinical trials currently underway for minors and 152 different trials involving seniors."

Answered by AI

How can I become a subject in this experiment?

"This psoriasis study, which will enroll 40 individuals in total, is seeking out participants that are between 18 and 99 years old."

Answered by AI

Are there any harmful side-effects associated with Duobrii 0.01 % / 0.045 % Topical Lotion?

"We believe that Duobrii 0.01 % / 0.045 % Topical Lotion is safe to use based on its Phase 3 status-- meaning there is both some evidence of efficacy and multiple rounds of data supporting safety."

Answered by AI
~13 spots leftby Mar 2025